Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Oxford BioMedica's share price for the quarter that ended in Dec. 2025 was £6.17. Oxford BioMedica's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 120.8 Mil. Therefore, Oxford BioMedica's market cap for the quarter that ended in Dec. 2025 was £745.0 Mil.
Oxford BioMedica's quarterly market cap
declined
from Dec. 2024 (£445.0 Mil) to Jun. 2025 (£335.9 Mil) but then
increased
from Jun. 2025 (£335.9 Mil) to Dec. 2025 (£745.0 Mil).
Oxford BioMedica's annual market cap
increased
from Dec. 2023 (£213.0 Mil) to Dec. 2024 (£445.0 Mil) and
increased
from Dec. 2024 (£445.0 Mil) to Dec. 2025 (£745.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Oxford BioMedica's Enterprise Value for Today is £817.4 Mil.
Oxford BioMedica (LSE:OXB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Oxford BioMedica Market Cap Related Terms
Oxford BioMedica Market Cap Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OXB vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Oxford BioMedica's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Market Cap distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Oxford BioMedica's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (LSE:OXB) has a Market Cap of £766.2 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #275 out of 1428 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Oxford BioMedica's Market Cap too high?
Oxford BioMedica's current Market Cap is £766.2 Mil. Based on the distribution chart, Oxford BioMedica ranks #275 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #275 out of 1428 companies for Market Cap. This places Oxford BioMedica in the top 19% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Market Cap is £766.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.33 — trading 18.1% above its estimated fair value. The current Market Cap is £766.2 Mil. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current Market Cap is £766.2 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of £6.33 is trading 18.1% above its estimated GF Value™ of £5.36.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for LSE:OXB:
Market Cap: £766.2 Mil
GF Value™: £5.36 vs. price of £6.33 (18.1% above fair value)
No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score
Get the complete analysis for LSE:OXB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OXB has been successfully added to your 
